SCHEMBL1746543

SCHEMBL1746543

COC(=O)c1cccc(CN(C)c2nc(-c3ccccc3)cs2)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.53
MEN1 O00255 4/20 0.53
L3MBTL1 Q9Y468 2/20 0.53
RAB9A P51151 4/20 0.47
NPC1 O15118 3/20 0.47
GSTO1 P78417 2/20 0.47
NPSR1 Q6W5P4 1/20 0.47
GRM1 Q13255 1/20 0.47
ALOX15 P16050 1/20 0.47
CPB1 P15086 1/20 0.47
ROCK2 O75116 2/20 0.46
ROCK1 Q13464 2/20 0.46
TP53 P04637 2/20 0.46
ALDH1A1 P00352 1/20 0.46
GAA P10253 1/20 0.46
GABRG2 P18507 1/20 0.45
GABRB3 P28472 1/20 0.45
GABRA5 P31644 1/20 0.45
GABRA3 P34903 1/20 0.45
LMNA P02545 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1747338 0.88 KMT2A (0.56) KMT2AMEN1L3MBTL1RAB9ANPC1
SCHEMBL3909417 0.86 KMT2A (0.49) KMT2AMEN1L3MBTL1RAB9ANPC1
SCHEMBL1745545 0.81 KMT2A (0.54) KMT2AMEN1L3MBTL1RAB9ANPC1
SCHEMBL18674599 0.80 KMT2A (0.64) KMT2AMEN1L3MBTL1RAB9ANPC1
SCHEMBL1746621 0.78 KMT2A (0.60) KMT2AMEN1L3MBTL1RAB9ANPC1
SCHEMBL5585520 0.77 TLR8 (0.44) KMT2AMEN1L3MBTL1RAB9ANPC1
SCHEMBL1745362 0.77 NPSR1 (0.48) KMT2AMEN1L3MBTL1GSTO1NPSR1
SCHEMBL1744789 0.75 KMT2A (0.54) KMT2AMEN1L3MBTL1RAB9ANPC1
SCHEMBL3451487 0.75 KMT2A (0.54) KMT2AMEN1L3MBTL1RAB9ANPC1
SCHEMBL1746853 0.75 FFAR1 (0.57)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1559422-B1 RECEPTOR FUNCTION CONTROLLING AGENT TAKEDA PHARMACEUTICAL (JP) 2014-04-30 EP disclosed
EP-2385032-A1 GPR40 Receptor function regulator Takeda Pharmaceutical Company Limited (JP) 2011-11-09 EP disclosed
US-7960369-B2 Receptor function regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-06-14 US disclosed
US-20090012093-A1 Receptor Function Regulator TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2009-01-08 US disclosed
EP-1559422-A1 RECEPTOR FUNCTION CONTROLLING AGENT Takeda Pharmaceutical Company Limited (JP) 2005-08-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090012093-A1 Receptor Function Regulator GPR119, GIPR, INSR KMT2A 4408/4885MEN1 2579/4885L3MBTL1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.